Bone Marrow Transplantation

• 

  Subject Areas on Research

  • 27. Transplantation immunology: organ and bone marrow. 
  • 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. 
  • A 17-Year-Old Boy With Right Face Palsy, Left Leg Weakness, and Lytic Skull-Bone Lesions. 
  • A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis. 
  • A cell-intrinsic role for CaMKK2 in granulocyte lineage commitment and differentiation. 
  • A clinical review: cutaneous manifestations of acute and chronic graft-versus-host disease following bone marrow transplantation. 
  • A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. 
  • A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. 
  • A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation. 
  • A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells. 
  • A historical review of bone marrow transplantation for immunodeficiencies. 
  • A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice. 
  • A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. 
  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. 
  • A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. 
  • A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. 
  • A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. 
  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. 
  • A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. 
  • A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. 
  • A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. 
  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. 
  • A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. 
  • A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. 
  • A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. 
  • A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. 
  • A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. 
  • A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. 
  • A virtual reality simulator for bone marrow harvest for pediatric transplant. 
  • ASBMT committee report: white paper on measurement of quality outcomes. 
  • ASBMT policy statement regarding the methodology of evidence-based reviews in evaluating the role of blood and marrow transplantation in the treatment of selected diseases. American Society for Blood and Marrow Transplantation. 
  • Abdominal complications in organ transplant recipients. 
  • Abnormal development of thymic dendritic and epithelial cells in human X-linked severe combined immunodeficiency. 
  • Accelerated development of immunity following transplantation of maternal marrow stem cells into infants with severe combined immunodeficiency and transplacentally acquired lymphoid chimerism. 
  • Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. 
  • Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma. 
  • Acute and chronic graft-versus-host disease in man. 
  • Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. 
  • Acute leukemia in children. 
  • Acute myelogenous leukemia associated with Ollier disease. 
  • Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. 
  • Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. 
  • Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients. 
  • Adoptively transferred immunity persists in human marrow graft recipients. 
  • Advances in the correction of immunodeficiency by bone marrow transplantation. 
  • Advances in the diagnosis and treatment of primary immunodeficiency diseases. 
  • Advances in the understanding and treatment of human severe combined immunodeficiency. 
  • Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. 
  • Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. 
  • Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. 
  • Allogeneic bone marrow transplantation for aplastic anemia and acute leukemia. 
  • Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. 
  • Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. 
  • Allogeneic marrow transplantation for acute leukemia in relapse. 
  • Allogeneic marrow transplantation for acute lymphoblastic leukemia in remission using fractionated total body irradiation. 
  • Allogeneic marrow transplantation for acute non-lymphoblastic leukemia in relapse using fractionated total body irradiation. 
  • Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. 
  • Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. 
  • Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Allogeneic marrow transplantation for patients with acute non-lymphoblastic leukemia in second remission. 
  • Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. 
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. 
  • Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. 
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. 
  • Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. 
  • Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse. 
  • Allogeneic marrow transplantation. 
  • Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. 
  • Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide. 
  • Alterations in L-selectin expression and elastase activity in neutrophils from patients receiving granulocyte colony-stimulating factor alone or in conjunction with high-dose chemotherapy with autologous bone marrow transplantation. 
  • Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. 
  • Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. 
  • Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. 
  • Alveolar rhabdomyosarcoma that metastasized to the orbit. 
  • Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. 
  • An immunoglobulin C kappa-reactive single chain antibody fusion protein induces tolerance through receptor editing in a normal polyclonal immune system. 
  • An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication. 
  • Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. 
  • Analysis of late infections in 89 long-term survivors of bone marrow transplantation. 
  • Angiotensin II mobilizes spleen monocytes to promote the development of abdominal aortic aneurysm in Apoe-/- mice. 
  • Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. 
  • Antibodies are back for thymic attack in cGVHD. 
  • Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. 
  • Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. 
  • Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. 
  • Antithymocyte globulin: a realistic approach to therapy for severe aplastic anemia. 
  • Appearance of multiple benign paraproteins during early engraftment of soy lectin T cell-depleted haploidentical bone marrow cells in severe combined immunodeficiency. 
  • Assessing surge capacity for radiation victims with marrow toxicity. 
  • Assessment and management of donor pain following marrow harvest for allogeneic bone marrow transplantation. 
  • Association between cyclosporin neurotoxicity and hypomagnesaemia. 
  • Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. 
  • Association of reticular dysgenesis (thymic alymphoplasia and congenital aleukocytosis) with bilateral sensorineural deafness. 
  • Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. 
  • Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. 
  • Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury. 
  • Autologous bone marrow transplantation for acute lymphoblastic leukemia. 
  • Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. 
  • Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. 
  • Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. 
  • Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary report. 
  • Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. 
  • Avascular necrosis following bone marrow transplantation: a case-control study. 
  • B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? 
  • Barriers to bone marrow transplantation for sickle cell anemia. 
  • Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. 
  • Bone Marrow Aspirate Concentrate for Bone Healing in Foot and Ankle Surgery. 
  • Bone density loss during treatment of chronic GVHD. 
  • Bone marrow and thymus transplantation in ataxia-telangiectasia. 
  • Bone marrow chimeras and c-fms conditional ablation (Mafia) mice reveal an essential role for resident myeloid cells in lipopolysaccharide/TLR4-induced corneal inflammation. 
  • Bone marrow transplantation augments the effect of brain- and spinal cord-directed adeno-associated virus 2/5 gene therapy by altering inflammation in the murine model of globoid-cell leukodystrophy. 
  • Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia. 
  • Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. 
  • Bone marrow transplantation for hematologic malignancies: the Stanford experience. 
  • Bone marrow transplantation for non-malignant disease. 
  • Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. 
  • Bone marrow transplantation for sickle cell disease. 
  • Bone marrow transplantation for sickle cell disease. 
  • Bone marrow transplantation for sickle cell disease. The United States experience. 
  • Bone marrow transplantation for thalassemia. The USA experience. 
  • Bone marrow transplantation from histocompatible sibling donors for patients with acute lymphoblastic leukemia. 
  • Bone marrow transplantation in patients aged 45 years and older. 
  • Bone marrow transplantation in the perinatal period. 
  • Bone marrow transplantation transfers age-related susceptibility to neovascular remodeling in murine laser-induced choroidal neovascularization. 
  • Bone marrow transplantation. Part I--Allogeneic. 
  • Bone marrow transplantation. Part II--autologous. 
  • Bone marrow transplantation: what is the question? 
  • Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. 
  • Both hematopoietic-derived and non-hematopoietic-derived {beta}-arrestin-2 regulates murine allergic airway disease. 
  • Brain radiation injury leads to a dose- and time-dependent recruitment of peripheral myeloid cells that depends on CCR2 signaling. 
  • Breakthroughs in the understanding and therapy of primary immunodeficiency. 
  • Bridging the gaps: using an NHP model to predict single dose radiation absorption in humans. 
  • Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. 
  • Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. 
  • Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. 
  • CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. 
  • CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. 
  • CD83 expression influences CD4+ T cell development in the thymus. 
  • CREB coactivators CRTC2 and CRTC3 modulate bone marrow hematopoiesis. 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Cannulated screw delivery of bone marrow aspirate concentrate to a stress fracture nonunion: technique tip. 
  • Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. 
  • Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. 
  • Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism. 
  • Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. 
  • Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. 
  • Changes in actin state and chemotactic peptide receptor expression in granulocytes during cytokine administration after autologous bone marrow transplantation. 
  • Changing trends in marrow transplantation for aplastic anemia. 
  • Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. 
  • Chemotherapy-induced eccrine squamous syringometaplasia in an infant. 
  • Childhood leukemia: the past, the present, and the future. 
  • Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. 
  • Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation. 
  • Chronic Graft-versus-Host Disease: A Long Road Ahead. 
  • Chronic cutaneous graft-versus-host disease in man. 
  • Chronic graft-versus-host disease and other late complications of bone marrow transplantation. 
  • Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. 
  • Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories. 
  • Chronic graft-versus-host disease. 
  • Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. 
  • Chronic myopathy due to immunoglobulin light chain amyloidosis. 
  • Cirrhosis of the liver in long-term marrow transplant survivors. 
  • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. 
  • Clinical intestinal transplantation: new perspectives and immunologic considerations. 
  • Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. 
  • Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. 
  • Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. 
  • Clonal contributions of small numbers of retrovirally marked hematopoietic stem cells engrafted in unirradiated neonatal W/Wv mice. 
  • Clostridium septicum abscess in hepatic metastases: successful medical management. 
  • Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells. 
  • Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. 
  • Colony-stimulating factors: clinical applications. 
  • Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. 
  • Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. 
  • Combined simultaneous kidney/bone marrow transplantation. 
  • Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Comparative trials of chemotherapy and bone marrow transplantation in acute nonlymphocytic leukemia. 
  • Comparison of intracardiac cell transplantation: autologous skeletal myoblasts versus bone marrow cells. 
  • Compatibility factors influencing the acceptance of rat bone marrow graft by the irradiated mouse. 
  • Complete DiGeorge syndrome: persistence of profound immunodeficiency. 
  • Complications of allogeneic bone marrow transplantation. 
  • Composite tissue allotransplantation: current challenges. 
  • Composite tissue allotransplantation: past, present and future-the history and expanding applications of CTA as a new frontier in transplantation. 
  • Congress review: progress and prospects in bone marrow transplantation. 
  • Conservative Management and Biological Treatment Strategies: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle. 
  • Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. 
  • Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. 
  • Conversion of indwelling chest port catheters to tunneled central venous catheters. 
  • Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. 
  • Coronary artery occlusion secondary to graft versus host disease after bone marrow transplant in a 21-year-old. 
  • Correction of purine nucleoside phosphorylase deficiency by transplantation of allogeneic bone marrow from a sibling. 
  • Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. 
  • Course of Crohn's disease after allogeneic marrow transplantation. 
  • Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. 
  • Current State of Stem Cell Therapy for Ischemic Heart Disease. 
  • Current and future preparative regimens for bone marrow transplantation in thalassemia. 
  • Current status of bone marrow transplantation. 
  • Customization of the TRU-PBMT App (Technology Recordings to better Understand Pediatric Blood and Marrow Transplant). 
  • Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. 
  • Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. 
  • Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation. 
  • Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. 
  • DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. 
  • Decompressive hemicraniectomy in pediatric patients with malignant middle cerebral artery infarction: case series and review of the literature. 
  • Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. 
  • Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. 
  • Delayed cardiac xenograft rejection in a pig-to-baboon model treated with a tolerance-inducing regimen and donor bone marrow infusion. 
  • Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. 
  • Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. 
  • Development of a model of melphalan-induced gastrointestinal toxicity in mice. 
  • Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. 
  • Development of bullous pemphigoid after allogeneic bone marrow transplantation. Report of a case. 
  • Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. 
  • Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. 
  • Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency. 
  • Development of systemic lupus erythematosus following autologous bone marrow transplant for acute lymphocytic leukemia. 
  • Diagnosis of posttransplant granulocytic sarcoma by fine-needle aspiration cytology and flow cytometry. 
  • Diagnostic challenge in recurrent skin rash after autologous bone marrow transplantation. 
  • Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. 
  • Disseminated Nocardia caviae with positive blood cultures. 
  • Donor bone marrow infusion in deceased and living donor renal transplantation. 
  • Donor bone marrow infusions are tolerogenic in human renal transplantation. 
  • Donor buffy coat cell infusion after marrow transplantation for aplastic anemia. 
  • Donor cell leukemia developing six years after marrow grafting for acute leukemia. 
  • Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis. 
  • Donor specific bone marrow cells suppress lymphocyte reactivity to donor antigens and differentially modulate TH1 and TH2 cytokine gene expression in the responder cell population. 
  • Donor type natural killer cells after haploidentical T cell-depleted bone marrow stem cell transplantation in a patient with adenosine deaminase-deficient severe combined immunodeficiency. 
  • Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. 
  • Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. 
  • Dynamic assessment of quality of life after autologous bone marrow transplantation. 
  • EFFECTS OF 6-AZAURIDINE ON REGENERATING BONE MARROW. 
  • Early HSCT corrects the skeleton in MPS. 
  • Early and late interstitial pneumonia following human bone marrow transplantation. 
  • Economic evaluation of high-dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or IIIA with more than 10 positive lymph nodes at surgical excision. 
  • Economics of bone marrow transplantation. 
  • Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. 
  • Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. 
  • Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. 
  • Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. 
  • Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 
  • Effects of chemotherapy and tamoxifen on cervical and vaginal smears in bone marrow transplant recipients. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. 
  • Effects of treatment regimens on post marrow transplant relapse. 
  • Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model. 
  • Efficacy of intensive care for bone marrow transplant patients with respiratory failure. 
  • Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. 
  • Elevated IgE and atopy in patients treated for early-onset ADA-SCID. 
  • Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantation. 
  • Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA). 
  • Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. 
  • Epstein-Barr-associated leiomyomatosis and T-cell chimerism after haploidentical bone marrow transplantation for severe combined immunodeficiency disease. 
  • Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. 
  • Esophageal abnormalities in chronic graft-versus-host disease in humans. 
  • Ethical considerations of using a single minor donor for three bone marrow harvests for three HLA-matched siblings with primary immunodeficiency. 
  • Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. 
  • Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. 
  • Evaluation of an automated technique for assessment of marrow engraftment after allogeneic bone marrow transplantation using a commercially available kit. 
  • Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. 
  • Ex vivo spermine dialdehyde treatment prevents lethal GVHD in a murine bone marrow transplantation model. 
  • Examination of the mechanisms responsible for tolerance induction after intrathymic inoculation of allogeneic bone marrow. 
  • Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment. 
  • Extended follow-up in 212 long-term allogeneic bone marrow transplant survivors. Issues of quality of life. 
  • FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 
  • FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 
  • Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. 
  • Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. 
  • Fanconi's anemia treated by allogeneic marrow transplantation. 
  • Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan. 
  • Fatal noncutaneous visceral infection with varicella-zoster virus in a patient with lymphoma after autologous bone marrow transplantation. 
  • Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. 
  • Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. 
  • Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes. 
  • Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. 
  • Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. 
  • Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 
  • Frizzled 9 knock-out mice have abnormal B-cell development. 
  • Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma. 
  • Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency. 
  • Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. 
  • G-CSF and peripheral blood progenitor cells. 
  • Gastric graft-versus-host disease: a blinded histologic study. 
  • Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. 
  • Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. 
  • Gene therapy in transplantation. 
  • Generation of bone marrow and fetal liver chimeric mice. 
  • Genetic engineering of mesenchymal stem cells and its application in human disease therapy. 
  • Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. 
  • Graft hyporeactivity induced by donor-derived dendritic cell progenitors. 
  • Graft versus host disease following allogeneic bone marrow transplantation. 
  • Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva. 
  • Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. 
  • Graft-extrinsic cells predominate in vein graft arterialization. 
  • Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. 
  • Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. 
  • Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. 
  • Graft-versus-host disease prevention by rapamycin: cellular mechanisms. 
  • Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. 
  • Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation. 
  • Graft-versus-host reactions: anti-leukemia effects of donor T cells. 
  • Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. 
  • Graft-versus-leukemia in the rat--the antileukemic efficacy of syngeneic and allogeneic graft-versus-host disease. 
  • Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. 
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. 
  • Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. 
  • Growth and development after bone marrow transplantation. 
  • Growth and development following marrow transplantation for leukemia. 
  • Growth and development in children after bone marrow transplantation. 
  • Growth hormone accelerates immune recovery following allogeneic T-cell-depleted bone marrow transplantation in mice. 
  • Guanine arabinoside as a bone marrow-purging agent. 
  • Guillain-Barre syndrome in organ and bone marrow transplant patients. 
  • Gynecologic manifestations of chronic graft-versus-host disease. 
  • Gynecological abnormalities following allogeneic bone marrow transplantation. 
  • HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci. 
  • HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. 
  • Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. 
  • Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. 
  • Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group. 
  • Heart xenograft survival with chimeric pig donors and modest immune suppression. 
  • Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. 
  • Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. 
  • Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. 
  • Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. 
  • Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. 
  • Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. 
  • Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. 
  • High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. 
  • High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. 
  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. 
  • High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. 
  • High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. 
  • High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. 
  • High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. 
  • High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. 
  • High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. 
  • High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. 
  • High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. 
  • High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. 
  • High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. 
  • Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. 
  • Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. 
  • Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. 
  • Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. 
  • Hypertension and reversible myocardial depression associated with autologous bone marrow transplantation. 
  • IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. 
  • Imaging findings of hemorrhagic cystitis in pediatric oncology patients. 
  • Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. 
  • Immune deficiency and expanded population of granular lymphocytes after bone marrow transplantation. 
  • Immune lymphocyte survival after chemotherapy and radiation. 
  • Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. 
  • Immunoglobulin therapy in bone marrow transplantation. 
  • Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. 
  • Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. 
  • Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. 
  • Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. 
  • Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. 
  • Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. 
  • Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. 
  • Immunoreconstitution. 
  • Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. 
  • Impact of a randomized, controlled trial of liberal vs conservative hospital discharge criteria on energy, protein, and fluid intake in patients who received marrow transplants. 
  • Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. 
  • Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. 
  • Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. 
  • Impaired CD8(+) T cell immunity after allogeneic bone marrow transplantation leads to persistent and severe respiratory viral infection. 
  • Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. 
  • In utero transplantation of rat hematopoietic stem cells induces xenogeneic chimerism in mice. 
  • In vivo engineering of bone tissues with hematopoietic functions and mixed chimerism. 
  • In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. 
  • Incompatible bone-marrow transplantation in lymphopenic immunologic deficiency. Circumvention of fatal graft-versus-host disease by immunologic enhancement. 
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. 
  • Individualizing treatment decisions for older adults with hematologic malignancies. 
  • Infection with varicella-zoster virus after marrow transplantation. 
  • Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. 
  • Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. 
  • Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. 
  • Interleukin 7 receptor alpha-chain-mutation severe combined immunodeficiency without lymphopenia: correction with haploidentical T-cell-depleted bone marrow transplantation. 
  • Intestinal and hepatic complications of human bone marrow transplantation. Part I. 
  • Intestinal and hepatic complications of human bone marrow transplantation. Part II. 
  • Intracardiac transplantation of a mixed population of bone marrow cells improves both regional systolic contractility and diastolic relaxation. 
  • Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion. 
  • Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation. 
  • Intravenous immune globulin prophylaxis in recipients of a marrow transplant. 
  • Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. 
  • Introduction to a symposium on sickle cell anemia: current results of comprehensive care and the evolving role of bone marrow transplantation. 
  • Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. 
  • Irgm1 protects hematopoietic stem cells by negative regulation of IFN signaling. 
  • Iterative generalized least squares for meta-analysis of survival data at multiple times. 
  • L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation. 
  • Late complications after marrow transplantation. 
  • Late complications of allogeneic and autologous marrow transplantation. 
  • Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. 
  • Leukocyte-derived IL-10 reduces subepithelial fibrosis associated with chronically inhaled endotoxin. 
  • Long term effects and quality of life in children and adults after marrow transplantation. 
  • Long- and short-lived murine hematopoietic stem cell clones individually identified with retroviral integration markers. 
  • Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. 
  • Long-term complications of bone marrow transplantation. 
  • Long-term engraftment following in utero T cell-depleted parental marrow transplantation into fetal rhesus monkeys. 
  • Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. 
  • Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. 
  • Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. 
  • Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. 
  • Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. 
  • Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy. 
  • Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. 
  • Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). 
  • Long-term outcome after marrow transplantation for severe aplastic anemia. 
  • Long-term outcome of non-ablative booster BMT in patients with SCID. 
  • Long-term results of allogeneic bone marrow transplantation. 
  • Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome). 
  • Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. 
  • Low serum thymic hormone levels in patients with chronic graft-versus-host disease. 
  • Low-dose radiation for posttransplant lymphoproliferative disorder. 
  • Lymphocyte accumulation in the spleen of retinoic acid receptor-related orphan receptor gamma-deficient mice. 
  • Lymphopenic immunologic deficiency in identical twins: lymphocyte allografting and graft-versus-host disease following treatment with albumin-gradient-separated paternal bone marrow cells. 
  • Lymphoproliferative disorders: CT findings in immunocompromised children. 
  • MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. 
  • Macrophage cells secrete factors including LRP1 that orchestrate the rejuvenation of bone repair in mice. 
  • Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. 
  • Management of cholelithiasis in pediatric patients who undergo bone marrow transplantation. 
  • Marrow cell transplantation for infantile hypophosphatasia. 
  • Marrow harvesting from normal donors. 
  • Marrow transplant experience for children with severe aplastic anemia. 
  • Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. 
  • Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide--a phase I trial. 
  • Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. 
  • Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience. 
  • Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease. 
  • Marrow transplantation for aplastic anemia. 
  • Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. 
  • Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. 
  • Marrow transplantation for disorders of hematopoiesis. 
  • Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. 
  • Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. 
  • Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. 
  • Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. 
  • Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission. 
  • Marrow transplantation for severe aplastic anemia and thalassemia major. 
  • Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. 
  • Marrow transplantation for thalassaemia. 
  • Marrow transplantation from HLA-identical siblings for treatment of aplastic anemia: is exposure to marrow donor blood products 24 hours before high-dose cyclophosphamide needed for successful engraftment? 
  • Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. 
  • Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. 
  • Marrow transplantation in hepatitis-associated aplastic anemia. 
  • Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. 
  • Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. 
  • Mast cell regulation of inflammation and gene expression during antigen-induced bladder inflammation in mice. 
  • Mechanically ventilated pediatric stem cell transplant recipients: effect of cord blood transplant and organ dysfunction on outcome. 
  • Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model. 
  • Mechanistic target of rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function. 
  • Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy statement by the American Society for Blood and Marrow Transplantation. 
  • Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. 
  • Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? 
  • Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. 
  • MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. 
  • Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. 
  • Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia. 
  • Mn(III) meso-tetrakis-(N-ethylpyridinium-2-yl) porphyrin mitigates total body irradiation-induced long-term bone marrow suppression. 
  • Modified MHC restriction of donor-origin T cells in humans with severe combined immunodeficiency transplanted with haploidentical bone marrow stem cells. 
  • Modified responses to recipient and donor B cells by genetically donor T cells from human haploidentical bone marrow chimeras. 
  • Modulation of one of three murine bone marrow stromal cell lines to adipose cells by serum and insulin. 
  • Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. 
  • Monoclonal B cell lymphocytosis: clinical and population perspectives. 
  • Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. 
  • Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. 
  • Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. 
  • Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. 
  • Myasthenia gravis after allogeneic bone marrow transplantation: relationship to chronic graft-versus-host disease. 
  • Mycobacterial infections in marrow transplant patients. 
  • Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. 
  • Mycoses in the transplanted patient. 
  • Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. 
  • Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. 
  • Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. 
  • Myocardial ischemia associated with high-dose carmustine infusion. 
  • NCCN Practice Guidelines for Chronic Myelogenous Leukemia. 
  • Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. 
  • Natural-killer-cell function and bone marrow transplantation. 
  • Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. 
  • Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. 
  • New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. 
  • New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. 
  • Non-Hodgkin's lymphoma. Biologic classification and implication for therapy. 
  • Nonvascularized bone grafting defers joint arthroplasty in hip osteonecrosis. 
  • Notch1 perturbation of hemopoiesis involves non-cell- autonomous modifications. 
  • Novel role for surfactant protein A in gastrointestinal graft-versus-host disease. 
  • Nutritional issues in adolescents after bone marrow transplant: a literature review. 
  • ONZIN deficiency attenuates contact hypersensitivity responses in mice. 
  • Obesity in pediatric oncology. 
  • Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. 
  • Ocular manifestations of graft-v-host disease. 
  • Ocular toxicity following high dose chemotherapy and autologous transplant. 
  • Opportunistic fungal pneumonia. 
  • Oral and ophthalmic pathology of graft versus host disease in man: predictive value of the lip biopsy. 
  • Oral manifestations of chronic graft-v-host disease. 
  • Oral manifestations of the chronic graft-v-host reaction. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. 
  • Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. 
  • Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. 
  • Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. 
  • Ovarian function following marrow transplantation for aplastic anemia or leukemia. 
  • PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. 
  • PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice. 
  • Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. 
  • Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. 
  • Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. 
  • Perioperative donor bone marrow infusion in cadaver kidney transplant recipients. 
  • Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. 
  • Peripheral blood stem cell harvesting and CD34-positive cell selection. 
  • Phagocytosis and clearance of apoptotic cells is mediated by MER. 
  • Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. 
  • Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. 
  • Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. 
  • Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation. 
  • Pleiotrophin mediates hematopoietic regeneration via activation of RAS. 
  • Pluripotency of mesenchymal stem cells derived from adult marrow. 
  • Pneumonia due to Fonsecaea pedrosoi and cerebral abscesses due to Emericella nidulans in a bone marrow transplant recipient. 
  • Pneumonia in bone marrow transplant patients. 
  • Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. 
  • Polymyositis as a manifestation of chronic graft-versus-host disease. 
  • Positive Family History, Infection, Low Absolute Lymphocyte Count (ALC), and Absent Thymic Shadow: Diagnostic Clues for All Molecular Forms of Severe Combined Immunodeficiency (SCID). 
  • Positive selection of CD34+ hematopoietic progenitor cells for transplantation. 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Post-transplantation B cell function in different molecular types of SCID. 
  • Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. 
  • Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. 
  • Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. 
  • Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. 
  • Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. 
  • Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation. 
  • Prevention and treatment of graft-versus-host disease. 
  • Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. 
  • Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. 
  • Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. 
  • Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. 
  • Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase. 
  • Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. 
  • Primary cellular immunodeficiencies. 
  • Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice. 
  • Properties of mouse leukemia viruses. XIII. Serum therapy of virus-induced murine leukemias. 
  • Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. 
  • Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. 
  • Prophylaxis of cytomegalovirus disease in allogeneic bone marrow transplantation. 
  • Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. 
  • Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. 
  • Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team. 
  • Prospects for treatment of human retrovirus-associated diseases. 
  • Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 
  • Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. 
  • Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. 
  • Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. 
  • Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. 
  • Purging multidrug resistant cells from bone marrow. 
  • Purging of autologous bone marrow for transplantation: the protection and selection of the hematopoietic progenitor cell. 
  • Quality of life after bone marrow transplantation. 
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. 
  • Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. 
  • Quality of life of adult long-term survivors of bone marrow transplantation: a qualitative analysis of narrative data. 
  • Radiation disasters: role of the BMT team. 
  • Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. 
  • Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. 
  • Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. 
  • Recognition, incidence, and management of oral graft-versus-host disease. 
  • Recombinant leukocyte A interferon for the treatment of serious viral infections after marrow transplant: a phase I study. 
  • Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. 
  • Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. 
  • Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease. 
  • Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. 
  • Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. 
  • Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. 
  • Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. 
  • Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial. 
  • Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. 
  • Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. 
  • Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. 
  • Repeat Cell Therapy for Refractory Angina: Déjà vu All Over Again? 
  • Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. 
  • Resolution of lung inflammation by CD44. 
  • Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. 
  • Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery. 
  • Retinopathy and optic neuropathy after transplantation. 
  • Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. 
  • Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings. 
  • Risk factors for airflow obstruction in recipients of bone marrow transplants. 
  • Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. 
  • Rolandic encephalopathy and epilepsia partialis continua following bone marrow transplant. 
  • Role of JAK3 in CD40-mediated signaling. 
  • Role of Transient Receptor Potential Vanilloid 4 in Neutrophil Activation and Acute Lung Injury. 
  • Role of autotransplantation in treatment of other solid tumors. 
  • Role of cytokines in autologous bone marrow transplantation. 
  • Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. 
  • Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. 
  • Second marrow infusion for poor graft function after allogeneic marrow transplantation. 
  • Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. 
  • Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. 
  • Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. 
  • Secondary cancers after bone marrow transplantation. 
  • Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin. 
  • Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. 
  • Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. 
  • Self-administration of morphine in bone marrow transplant patients reduces drug requirement. 
  • Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. 
  • Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. 
  • Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting. 
  • Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation. 
  • Severe combined immunodeficiency (SCID) with natural killer (NK) cell predominance. 
  • Severe combined immunodeficiency with natural killer-cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells. 
  • Spermine dialdehyde, a novel ex vivo purging agent for both allogenic and autologous bone marrow transplantations. 
  • Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. 
  • Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. 
  • State of the art in umbilical cord transplantation. 
  • Stem cell homing. 
  • Steps toward transplantation tolerance in the clinic. 
  • Strategies for tolerance induction in nonhuman primates. 
  • Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. 
  • Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency. 
  • Successful immune reconstitution in severe combined immunodeficiency despite Epstein-Barr virus and cytomegalovirus infections. 
  • Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. 
  • Supportive care of the marrow transplant recipient: the Seattle Experience. 
  • Surrogate tolerogenesis: possible pretransplant induction of accommodation of pig xenografts. 
  • Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. 
  • Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. 
  • Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. 
  • T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation. 
  • T lymphocyte depletion of human peripheral blood and bone marrow using monoclonal antibodies and magnetic microspheres. 
  • T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. 
  • Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. 
  • Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. 
  • Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain. 
  • Testing for the presence of cured patients: a simulation study. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. 
  • The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. 
  • The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. 
  • The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. 
  • The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. 
  • The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID). 
  • The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. 
  • The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. 
  • The effects of hyperthermia in bone marrow purging of breast cancer. 
  • The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. 
  • The ethical justification for minor sibling bone marrow donation: a case study. 
  • The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. 
  • The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. 
  • The extent of HLA class II allele level disparity in unrelated bone marrow transplantation: analysis of 1259 National Marrow Donor Program donor-recipient pairs. 
  • The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. 
  • The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. 
  • The long and the short of telomeres in bone marrow recipient SCID patients. 
  • The management of chronic graft-versus-host disease. 
  • The meaning of adolescents' eating experiences during bone marrow transplant recovery. 
  • The multifunctional Ca²⁺/calmodulin-dependent kinase IIδ (CaMKIIδ) regulates arteriogenesis in a mouse model of flow-mediated remodeling. 
  • The oncogenic microRNA miR-21 promotes regulated necrosis in mice. 
  • The pathophysiology and treatment of graft-versus-host disease. 
  • The potential of xenotransplants. 
  • The predictive value of elevated labial saliva sodium concentration: its relation to labial gland pathology in bone marrow transplant recipients. 
  • The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles. 
  • The role of adenotonsillectomy in graft-versus-host disease. 
  • The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. 
  • The significance of microbial cultures of the hematopoietic support for patients receiving high-dose chemotherapy. 
  • The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. 
  • The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. 
  • The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. 
  • Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. 
  • Thymus transplantation after allogeneic bone marrow graft to prevent chronic graft-versus-host disease in humans. 
  • Tissue and tumor mosaicism of the myotonin protein kinase gene trinucleotide repeat in a patient with multiple basal cell carcinomas associated with myotonic dystrophy. 
  • To stop or not to stop: how much support should be provided to mechanically ventilated pediatric bone marrow and stem cell transplant patients? 
  • Tolerance and immunity after sequential lung and bone marrow transplantation from an unrelated cadaveric donor. 
  • Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. 
  • Total hip arthroplasty in very young bone marrow transplant patients. 
  • Total lymphoid irradiation as an immunosuppressive agent for transplantation and the treatment of 'autoimmune' disease: a review. 
  • Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. 
  • Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. 
  • Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. 
  • Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. 
  • Transfusion effect on graft-versus-host disease and leukemic relapse in HLA-matched bone marrow transplantation. 
  • Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease. 
  • Transplantation immunology: solid organ and bone marrow. 
  • Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. 
  • Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. 
  • Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. 
  • Treatment choices in chronic myelogenous leukemia. 
  • Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. 
  • Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. 
  • Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. 
  • Treatment of advanced colorectal cancer. 
  • Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. 
  • Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. 
  • Treatment of infants with complete DiGeorge anomaly. 
  • Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. 
  • Treatment of marrow graft recipients with thymopentin. 
  • Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation. 
  • Treatment options for genetically determined immunodeficiency. 
  • Treatment strategies in childhood cancer. 
  • Treatment with immunotoxin. 
  • Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. 
  • Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. 
  • Umbilical cord blood: a novel alternative source of hematopoietic stem cells for bone marrow transplantation. 
  • Unicameral bone cyst: a retrospective study of three surgical treatments. 
  • Unique immunologic problems in human bone marrow transplant recipients. 
  • Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. 
  • Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry. 
  • Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. 
  • Unrelated donor marrow transplantation in children. 
  • Unrelated placental blood in marrow transplantation. 
  • Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency. 
  • Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. 
  • Use of amifostine in bone marrow purging. 
  • Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. 
  • Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years' follow-up. 
  • Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia. 
  • Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. 
  • Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. 
  • Validation of DNA-based HLA-A and HLA-B testing of volunteers for a bone marrow registry through parallel testing with serology. 
  • Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. 
  • Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. 
  • Weight gain and height velocity in young children 1 year following bone marrow transplant: a single institution study. 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
  • When you hear hoof beats...do not forget the zebras. 
  • White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. 
  • Wild-type Kras expands and exhausts hematopoietic stem cells. 
  • Xenotransplantation of baboon bone marrow cells: a historical review of the protocols as a possible treatment modality for HIV/AIDS. 
  • [Assessment of therapeutic results for simple bone cyst with percutaneous injection of autogenous bone marrow]. 
  • [Human herpesvirus type 6 and type 7 in transplant recipients]. 
  • [Porcine MSC-derived CLC induced by rabbit's cardiomyocytes extract did not induce immune reaction in vivo]. 
  • c-FLIP protects eosinophils from TNF-α-mediated cell death in vivo. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor of Pediatrics, in the School of Medicine, Immunology
  • Chen, Jun, Associate Professor of Medicine, Duke Cancer Institute
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology